Compare Bristol-Myers Squibb Co (BMY) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Western Digital Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.59 (market cap $116.30B), while Western Digital Corp trades at $520.8 (market cap $194.17B). The key difference: Western Digital Corp is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | WDC | |
|---|---|---|
Market Cap | $116.30B | $194.17B |
Sector | Health | Technology |
52-Week High | $62.37 | $746.23 |
52-Week Low | $42.60 | $66.53 |
Enterprise Value | $152.24B | $192.51B |
Dividend Yield | 4.42% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Western Digital (WDC) trades at $555.55, down 4.64% amid a sector-wide memory stock sell-off. The stock shows strong fundamentals with three consecutive quarterly EPS beats, a net income margin of 55.07%, and robust cash flow from operations of $1.69B in 2025. Technical indicators are bearish, with price near the pivot point of $551. Analyst sentiment remains overwhelmingly positive with a 72% buy rating and a $619.07 consensus price target, suggesting significant upside potential.
The outlook is supported by AI-driven storage demand and margin expansion, but near-term volatility from memory pricing cycles and competitive pressures poses risks. The stock's high valuation multiples require sustained earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
